Genesis Molecular AI vs Iktos (2026)
Both build small molecule design platforms that their own chemists and their partners use. Genesis Molecular AI, a Stanford spinout, runs GEMS: generative models for ideation, multitask models for absorption, distribution, metabolism and excretion, and agents that handle routine steps while chemists decide what to make. Its Pearl model, released in October 2025, predicts protein ligand structures and can be fine tuned on a program's own data. Iktos, founded in Paris in 2016, sells software directly: Makya for generative design with synthetic accessibility built in, Spaya for retrosynthesis, and engine APIs, alongside robotic chemistry and discovery collaborations. Genesis is mainly a partner; Iktos can also be bought as software your team runs.
- Pearl, a protein ligand structure model trained on proprietary physics based synthetic data and fine tunable on a program's data.
- Measured results with denominators against named baselines.
- Agents that orchestrate routine work while chemists keep the decisions.
- Generative design as software, Makya, with synthesis built into generation.
- Retrosynthesis with Spaya, routing to commercially available starting materials.
- Robotic synthesis, purification and testing, and APIs that plug the models into a team's own workflows.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Genesis Molecular AI and Iktos are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Genesis Molecular AI | Iktos |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2016 |
| Headquarters | Burlingame, CA | Paris, France |
| Website | genesis.ml | iktos.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Genesis Molecular AI its top capability grade on AI Centrality. Set against Iktos, Genesis Molecular AI grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, September 2026
The AI Health Index awards Iktos its top capability grade on AI Centrality. Set against Genesis Molecular AI, Iktos grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and EHR and Interoperability Depth. Its thinnest published disclosure sits on HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, September 2026
Questions buyers ask
Should we choose Genesis Molecular AI or Iktos?
On the axes where the AI Health Index separates them, Genesis Molecular AI grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse, and Iktos grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and EHR and Interoperability Depth. Iktos leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Genesis Molecular AI and Iktos differ most?
The widest separation the AI Health Index records between Genesis Molecular AI and Iktos is on AI Safety and PHI Stewardship, where Genesis Molecular AI grades D and Iktos grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Genesis Molecular AI and Iktos grade the same?
The AI Health Index grades Genesis Molecular AI and Iktos the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Genesis Molecular AI and Iktos not disclosed?
At the last review, at least one of Genesis Molecular AI and Iktos published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Neither publishes prices, and part of Iktos's published material could not be read for this review.
Ask both how a designed molecule that fails synthesis or testing is fed back into the models.